Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Morbid Obesity and Insulin Resistance
NCT02970877Phase 2Completed
- Start
- Mar 2017
- Primary completion
- Jun 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fecal microbiome transplant in class III obesity and insulin resistance (IR). Primary endpoint: Homeostatic Model Assessment for Insulin Resistance at 3 month. Started Mar 2017; status: completed.
02
Drugs
fecal microbiome transplant
03
Conditions
class III obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT02970877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970877.